FDA Fast Tracks CB-011 for Relapsed/Refractory Multiple Myeloma

The FDA granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.